

P & T Formulary Update	September 2010
Additions to Formulary:	<p><u>Abilify® Liquid (aripiprazole):</u> atypical antipsychotic</p> <ul style="list-style-type: none"> ▪ Liquid formulation is significantly less expensive than tablets. ▪ Switching to liquid equates to a cost savings of over \$90,000 over one year period. <p>Committee decision: approved removal of Abilify tablets and having only Abilify liquid available on formulary.</p> <p><u>Update on Tdap (Adacel®) for OB patients</u></p> <ul style="list-style-type: none"> ▪ Hospital administration approved Tdap for OB patients. ▪ Rollout will include screening and documentation of significant events in SCM as well as education for patients and nurses. <p><u>Cape Surgery Medications</u></p> <ul style="list-style-type: none"> ▪ Several eye drops and miscellaneous medications commonly used at Cape surgery are non-formulary at SMH. Suggestion to add these medications restricted to use in Cape with future review. <p>Committee decision: non-formulary medications added to formulary but restricted to use in Cape surgery.</p>

Therapeutic Substitutions	<p><u>Phosphate binder class review – Renvela® (sevelamer carbonate)</u></p> <ul style="list-style-type: none"> ▪ Renvela® – sevelamer carbonate versus Renagel – sevelamer HCL ▪ Equally efficacious at reducing PO4 levels ▪ Clinical significance of Renvela® to increase bicarbonate levels unproven <p>Committee decision: approved interchangeability of Renagel® and Renvela® at 1:1 ratio based on cost and availability. Removal of Fosrenal® based on increased cost and availability of other agents.</p> <p><u>Avandia® (rosiglitazone) and risk of MI</u></p> <ul style="list-style-type: none"> ▪ Controversy on this subject ▪ An alternative agent is available in the same class with a better safety profile (Actos®/pioglitazone). <p>Committee decision: approved removal of rosiglitazone and autosubstitution with pioglitazone.</p>
Formulary Deletions	<p><u>Thrombolytic class review – Retevase® (reteplase)</u></p> <ul style="list-style-type: none"> ▪ Not currently being utilized ▪ Last purchase was in Jan 2010 due to vial expiring (\$1,978) <p>Committee decision: removal of Retevase® from formulary.</p>
Other Formulary Initiatives	<p><u>New High Dose Fluzone</u></p> <ul style="list-style-type: none"> ▪ High dose flu vaccine indicated in adults 65 years and older. ▪ No correlation to improved outcomes has been reported <p>Committee decision: approved the decision to not add Fluzone to formulary.</p> <p><u>Oxycontin® (oxycodone CR) in post-op orthopedic patients</u></p> <ul style="list-style-type: none"> ▪ MSQI committee requested P&T revisit removal of Oxycontin® from post-op order sets ▪ The formation of a working group to determine the scope of the problem as well as solutions to help improve work flow and patient safety was suggested. <p>Committee decision: approved removal of Oxycontin® from order sets and formation of working group.</p>

Miscellaneous

Medication safety: Gadolinium-based contrast agents

- New labeling indicating Nephrogenic Systemic Fibrosis (NSF).
- Multihance (our formulary agent) has had no reports of NSF.
- Healthcare professionals are urged to screen patients to identify those with AKI or kidney disease
- Suggestion to assess what that GFR we restrict use of these agents and identify if a higher cutoff should be used (60ml/min vs. 30ml/min). Recommendations will be presented at the next meeting.

Medication recall and shortage

- Neoprofen® (ibuprofen lysine injection) has been recalled.
- We are currently using injectable indomethacin

Medication safety review – Quaaluan® (quinine sulfate)

- Adverse events have been reported with the use of this product.
- Removal of quinine for leg cramps has already been completed by the committee.

For more information on any of these items or a copy of the minutes, please email Amy Giovino, PharmD, Formulary Coordinator at amy-giovino@smh.com